ALAXIA

Alaxia is a biotech company developing therapeutic solutions for respiratory diseases. The most advanced drug candidate, ALX-009, is an antimicrobial compound aiming at treating lung infections including the most multidrug resistant bacterial strains. ALX-009, the company’s lead compound, is an antimicrobial product originally developed for CF patients to fight antibiotic multi-resistant Gram negative bacteria. Alaxia’s in vitro and ex vivo tests showed 100% efficacy on several strains (Burkholderia spp., MDR Pseudomonas aeruginosa, Achromobacter spp. and Stenotrophomonas spp.). ALX-009 is produced extemporaneously by dedicated equipment EOLEASE as and when needed. ALX-009 was developed to be administered by inhalation. In February 2020 Alaxia completed its phase 1 clinical trial cohorts enrolling 84 healthy volunteers (phase 1a) to study the safety profile of the compound. ALX-009 was deemed safe to inhale. The company has started recruiting CF and bronchiectasis patients at several EU clinical sites to complete this ongoing study (phase 1b). During summer 2020, Alaxia started to investigate the potential of ALX-009 on SARS-CoV-2. More info https://www.alaxia-pharma.eu/news “The promising effect on SARS-CoV-2 suggests that ALX-009 can be an antimicrobial with virucidal properties. With the phase 1 clinical trial data, we were able to determine that ALX-009 is a safe breathable antimicrobial drug candidate. It could be an important tool to treat a large array of life threatening agents in CF,” Warning: Please be aware that some people are fraudulently using our name and logo to offer fake jobs without our consent. We at Alaxia never ask job seekers to pay or purchase anything while applying for a job, nor cash in any check. Please do not respond to such proposals. Be sure that we are doing everything we can to stop these fraudulent actions. Only jobs announced on www.alaxia-pharma.eu and discuss with French team are real, others are fakes